Dr. Ashok Kumar Singh
Name: Dr. Ashok Kumar Singh
Qualification: Ph.D. in Pharmaceutical Sciences
Designation : Post Doctoral Trainee
Department: Pharmacology
institute name : Pennsylvania State University, Penn State College of Medicine, Hershey, PA, USA
College address : Penn State College of Medicine
500 University Drive
Hershey, PA 17033
Award for : Research Excellence Award
Publication title: Journal
Paper Title : Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals
Journal Name : Scientific Reports (Nature Publication)
Volume : 8
Issue No. : 1
month of publication : April
Year : 2018
page no. : 5932. doi: 10.1038/s41598-018-24288-0.
ISSN : 2045-2322
About Dr. Ashok Kumar Singh
Dr. Ashok Kumar Singh is currently an “Active, Certified and Recognized Reviewer” in various SCI
Indexed journals, aiming to bridge the gap between scientific research and industry professionals. He is also working actively as “Editorial Advisory Board Members” in four peer-reviewed scientific journals.
He holds a doctoral degree (March, 2019) in Pharmaceutical Sciences from BBAU, A Central
University, Lucknow. His doctoral research focuses on the “Design and synthesis of novel Indole fused benzo and pyrido heteroazepines (IFBOs & IFPOs) for the treatment of hepatocellular carcinoma (HCC) by IL-6 mediated JAK2/STAT3 oncogenic signaling blockade”. He joined the “Pennsylvania State University, Pennsylvania, USA” as a NIH funded postdoctoral fellow (July 2019) where he was certified with a post-doctoral trainee in the field of “Discovery of small molecules as cancer therapeutics”.
He received the Master degree (March, 2014) in Pharmaceutical Sciences from BBDNIIT, Lucknow, with successful completion of research project entitled “Microwave-assisted synthesis and molecular
modelling study of novel benzylidine thiazolidine-4-one fibrates as PPAR-α agonist”.
His past research was devoted to the “Discovery of novel molecules for the treatment of cancer,
diabetes and cardiovascular disease”. His thrust area of research is to identify the biomolecular targets of novel anti-cancer molecule at preclinical as well as clinical level. Further, he has thorough knowledge in synthetic organic chemistry, In Silico drug design and discovery, synthesis of novel molecules and their spectroscopic analysis, PK/PD study, in vitro and in vivo pharmacological screening, histopathology, SEM, ELISA and immunohistochemistry. Importantly, his major research is oriented towards the target identification of novel molecules using gene and protein expression and cell cycle arrest analysis utilizing qRT-PCR, Western blot and flow cytometry techniques, respectively. His current research is oriented towards the utilization of Artificial Intelligence (AI), Machine learning (ML) and Deep learning (DL) concepts in drug discovery.
He has extensive publications across various research domains where his more recent professional
publications include:
• Published more than 45 research papers and book chapters in various SCI/Scopus/Web of
Science indexed reputed journals including Nature, Elsevier, Springer, Taylor & Francis etc.
• Published 3 Indian patents based on “The discovery of novel candidate molecules to treat Liver
cancer”.
• Participated and presented in 17 national and international seminars, conferences and
workshops.
• Recently, he has awarded with 10 online certification courses, for example: Arti?cial
Intelligence in Drug Discovery, Machine learning and Deep learning in drug discovery, Methods
of prompt drug discovery for the treatment of COVID-19.
• Recently, Awarded with “Record of Achievements” from several scientific bodies including
“World Health Organization (WHO) and achieved “Certificate of Excellence” from Elsevier
Publication in various Scientific writing discipline, including Certified Peer Reviewer course,
Book writing, Research data management, Research collaborations and Social impact.
Additionally, at postgraduate level. he has qualified several scholastic exams including CSIR-UGC-NET
(from Chemical Sciences), GATE-2013 (from Life Sciences) and GPAT (from Pharmaceutical
Sciences) that reflect his sound multi-disciplinary knowledge and excellence in science.